BioLife Solutions
BLFS
38.61
0.00
0.00%
BioLife Solutions
US · BLFS
#2844 by market cap
Listed 1970
38.61
0.00
0.00%
Live - 5344 symbols - heartbeat 314s ago
· 2026-10-07 19:54
- Market cap
- 1.89B
- P/E (TTM)i
- 32.72
- P/Bi
- 4.50
- EPSi
- -0.10
- Div yieldi
- 0.00%
- 52W posi
- 95%
Reader sentiment
Are you bullish or bearish on BLFS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 32.60, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +28.89% YoY
Margins
- Gross margin
- 64.56%
- Operating margin
- -17.26%
- Net margin
- -4.78%
Key ratios & quality
- Altman Z-Scorei
- 32.60
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.74M | 27.37M | 48.09M | 119.16M | 76.24M | 68.02M | 74.65M | 96.21M |
| Gross profit | 13.53M | 18.61M | 27.44M | 37.05M | 46.91M | 41.32M | 50.10M | 62.12M |
| Selling & admin expenses | 8.57M | 13.59M | 21.69M | 47.67M | 44.93M | 54.17M | 49.56M | 55.37M |
| Research & development | 1.30M | 3.17M | 6.72M | 11.82M | 8.67M | 5.52M | 4.75M | 23.09M |
| Operating profit | 3.66M | 770.00K | -4.00M | -30.65M | -10.68M | -19.40M | -4.48M | -16.60M |
| Pretax profit | -25.01M | -3.20M | -1.28M | -29.03M | -4.85M | -12.22M | -8.82M | -12.08M |
| Tax | -- | -1.54M | -3.26M | -20.12M | -5.24M | -64.00K | -38.00K | 49.00K |
| Net profit | -25.01M | -1.66M | 1.98M | -8.91M | -139.81M | -68.00M | -20.18M | -4.60M |
| Basic EPS | -2 | 0 | 0 | 0 | -3 | -2 | 0 | 0 |
| Diluted EPS | -1.56 | -0.09 | -0.06 | -0.23 | -3.29 | -1.55 | -0.44 | -0.10 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 22.05M | 23.44M | 28.07M | 18.79M | 27.50M | 28.47M |
| Gross profit | 14.80M | 15.24M | 17.92M | 11.98M | 17.50M | 18.29M |
| Selling & admin expenses | 13.79M | 13.81M | 14.60M | 12.54M | 14.73M | 13.48M |
| Research & development | 1.44M | 17.49M | 2.71M | -67.00K | 2.65M | 2.96M |
| Operating profit | -499.00K | -16.13M | -89.00K | 1.35M | 27.00K | 1.70M |
| Pretax profit | 285.00K | -15.20M | 703.00K | 3.36M | 1.25M | 2.75M |
| Tax | 14.00K | 126.00K | 82.00K | -173.00K | 62.00K | -42.35M |
| Net profit | -448.00K | -15.84M | 621.00K | 11.07M | 1.19M | 45.10M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 1 |
| Diluted EPS | -0.01 | -0.33 | 0.01 | 0.22 | 0.02 | 0.91 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 37.56M | 24.11M | 114.71M | 126.09M | 138.45M | 120.60M | 148.76M | 136.56M |
| Cash & ST investments | 30.66M | 6.45M | 90.40M | 69.86M | 62.70M | 44.18M | 100.74M | 88.93M |
| Inventory | 3.51M | 10.97M | 11.60M | 28.35M | 34.90M | 27.16M | 29.01M | 30.16M |
| Total assets | 45.47M | 92.82M | 234.83M | 554.29M | 450.23M | 412.71M | 399.49M | 405.88M |
| Total current liabilities | 1.94M | 7.67M | 15.57M | 42.70M | 44.58M | 42.18M | 32.73M | 22.98M |
| Short-term debt | -- | 817.00K | 1.73M | 3.77M | 4.83M | 7.57M | 12.40M | 7.24M |
| Long-term debt | -- | -- | 655.00K | 6.35M | 23.79M | 17.56M | 5.00M | -- |
| Total liabilities | 30,835,000.00 | 49,362,000.00 | 29,583,000.00 | 76,239,000.00 | 86,041,000.00 | 75,051,000.00 | 50,578,000.00 | 33,996,000.00 |
| Total equity | 14.63M | 43.45M | 205.25M | 478.05M | 364.19M | 337.66M | 348.91M | 371.89M |
| Retained earnings | -98.40M | -100.05M | -97.39M | -107.11M | -246.92M | -314.92M | -335.10M | -339.70M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 131.13M | 125.43M | 126.57M | 136.56M | 133.22M | 135.20M |
| Cash & ST investments | 88.58M | 81.77M | 78.95M | 88.93M | 81.00M | 82.42M |
| Inventory | 27.57M | 27.69M | 27.83M | 30.16M | 32.83M | 35.59M |
| Total assets | 395.14M | 387.24M | 392.08M | 405.88M | 400.91M | 447.49M |
| Total current liabilities | 27.72M | 28.31M | 27.15M | 22.98M | 18.25M | 13.95M |
| Short-term debt | 12.28M | 12.22M | 9.67M | 7.24M | 4.82M | 2.59M |
| Long-term debt | 2.50M | -- | -- | -- | -- | -- |
| Total liabilities | 42,517,000.00 | 40,085,000.00 | 38,342,000.00 | 33,996,000.00 | 28,676,000.00 | 27,491,000.00 |
| Total equity | 352.62M | 347.16M | 353.74M | 371.89M | 372.23M | 420.00M |
| Retained earnings | -335.55M | -351.39M | -350.77M | -339.70M | -338.51M | -293.41M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.35M | 1.21M | 6.65M | -4.59M | -8.49M | -12.50M | 8.43M | 20.12M |
| Depreciation & amortization | 338.00K | 1.80M | 5.07M | 12.87M | 16.47M | 12.30M | 8.66M | 4.69M |
| Free cash flow | 1.85M | 538.00K | 2.01M | -12.98M | -18.87M | -18.88M | 4.90M | 416.00K |
| Dividends paid | -436.00K | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 20.00M | 0 | 100.12M | 0 | 0 | 10.24M | 0 | 0 |
| Ending cash balance | 30.66M | 6.45M | 90.46M | 69.87M | 19.47M | 35.44M | 95.39M | 33.04M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.73M | 7.37M | 6.10M | 4.92M | -491.00K | 6.35M |
| Depreciation & amortization | 1.38M | 1.38M | 1.34M | 586.00K | 699.00K | 809.00K |
| Free cash flow | 1.55M | 5.63M | 2.80M | -9.56M | -658.00K | 5.19M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 66.95M | 31.90M | 29.48M | 33.04M | 22.82M | 24.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 11.00 | -3.83 | 2.14 | -2.23 | -33.12 | -18.93 | -5.88 | -1.28 |
| ROA %i | 10.16 | -2.40 | 1.63 | -1.94 | -27.84 | -15.40 | -4.97 | -1.14 |
| ROIC %i | 10.24 | -4.53 | 2.01 | -2.11 | -30.56 | -16.85 | -5.32 | -1.20 |
| 5-year avg ROE %i | -- | -82.23 | -73.61 | -50.58 | -48.99 | -11.86 | -11.89 | -12.47 |
| EBIT margin %i | 16.57 | -11.67 | -6.93 | -24.70 | -24.67 | -40.16 | -8.67 | -17.26 |
| FCF / sales %i | 9.36 | 1.97 | 4.18 | -- | -- | -- | 5.96 | 0.43 |
| Current ratioi | 19.37 | 3.14 | 7.37 | 2.95 | 3.11 | 2.86 | 4.54 | 5.94 |
| Quick ratioi | 17.38 | 1.54 | 6.32 | 2.18 | 2.17 | 1.23 | 3.34 | 4.22 |
| Debt / assetsi | 0.00 | 1.47 | 4.75 | 4.85 | 9.71 | 8.20 | 7.52 | 4.41 |
| LT debt / equityi | -- | 1.27 | 4.59 | 4.83 | 10.68 | 7.78 | 5.06 | 2.87 |
| Interest coveragei | 654.20 | -638.60 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 45.20 | 49.29 | 63.40 | 82.07 | 40.70 | 12.25 | -14.43 | 8.07 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | 63.42 | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.04 | -1.65 | -0.94 | -1.28 | -0.82 | 15.12 |
| ROA %i | -2.61 | -1.45 | -0.83 | -1.14 | -0.74 | 13.89 |
| ROIC %i | -2.76 | -1.52 | -0.87 | -1.20 | -0.77 | 14.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -5.76 | 11.40 | -20.03 | -17.26 | -15.81 | 1.64 |
| FCF / sales %i | 12.86 | 12.25 | 10.55 | 0.43 | -- | -- |
| Current ratioi | 4.73 | 4.43 | 4.66 | 5.94 | 7.30 | 9.69 |
| Quick ratioi | 3.53 | 3.24 | 3.31 | 4.22 | 5.15 | 6.67 |
| Debt / assetsi | 6.82 | 6.15 | 5.27 | 4.41 | 3.71 | 3.52 |
| LT debt / equityi | 4.16 | 3.34 | 3.11 | 2.87 | 2.70 | 3.13 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
CryoStor100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.